Recurrent hypoglycemia in a patient with hepatocellular carcinoma
More details
Hide details
Department of Family Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, MALAYSIA
Online publication date: 2023-01-28
Publication date: 2023-05-01
Electron J Gen Med 2023;20(3):em465
Hypoglycemia is a common complication of diabetes mellitus. Patients may present with any kind of symptoms, either autonomic or neuroglycopenic. Here, we report a case of a 70-year-old man with type 2 diabetes mellitus with a newly diagnosed hepatocellular carcinoma presenting with recurrent episodes of hypoglycemia. The insulin treatment was withheld initially. However, the patient's diabetic control worsened after starting treatment for his hepatocellular carcinoma. Hence, the insulin treatment was resumed. This case highlighted the challenge in balancing the management of hypoglycaemia and poor diabetic control in a patient who has diabetes mellitus and hepatocellular carcinoma. Primary care practitioners need to have high clinical suspicion to monitor these patients to prevent hypoglycemia and manage them accordingly.
Hung TH, Tseng CW, Tsai CC, Lee HF. Prognosis of hypoglycemia episode in cirrhotic patients during hospitalization. BMC Gastroenterol. 2021;21(1):319. PMid:34372791 PMCid:PMC8351368.
Rojbi I, Ben Elhaj W, McHirgui N, Jrad M, et al. Non-islet-cell tumor hypoglycemia as first manifestation of an advanced hepatocellular carcinoma. Clin Case Rep. 2021;9(10):e05012.
Saad M, Hafeez S, Ogunko A, Mohandas C, Abedo IF, editors. A case of non-islet cell tumour hypoglycaemia due to advanced hepatocellular carcinoma secondary to previously undiagnosed chronic HBV-infection. Endocrine Abstracts; 2020: Bioscientifica.
Van den Berg S, Krol C. Pro-IGF2-induced hypoglycaemia associated with hepatocellular carcinoma. Endocrinol Diabetes Metab Case Rep. 2017;2017(1). PMid:28567293 PMCid:PMC5445433.
Graveling AJ, Frier BM. Impaired awareness of hypoglycaemia: a review. Diabetes Metab. 2010;36 Suppl 3:S64-74. PMid:21211739.
Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384-95. PMid:23589542 PMCid:PMC3631867.
Tsai CY, Chou SC, Liu HT, Lin JD, Lin YC. Persistent hypoglycemia as an early, atypical presentation of hepatocellular carcinoma: A case report and systematic review of the literature. Oncol Lett. 2014;8(4):1810-4. PMid:25202415 PMCid:PMC4156172.
Yu B, Douli R, Suarez JA, Gutierrez VP, Aldiabat M, Khan M. Non-islet cell tumor hypoglycemia as an initial presentation of hepatocellular carcinoma coupled with end-stage liver cirrhosis: A case report and review of literature. World J Hepatol. 2020;12(8):519-24. PMid:32952878 PMCid:PMC7475778.
North A, Thakkar R, James R, Hammond J. The palliative management of non-islet cell tumour hypoglycaemia with glucocorticoids and somatostatin analogues in an unresectable hepatocellular carcinoma. Ann R Coll Surg Engl. 2022;104(6):e180-e2. PMid:35133207.
Hershey DS. Importance of glycemic control in cancer patients with diabetes: Treatment through end of life. Asia Pac J Oncol Nurs. 2017;4(4):313-8. PMid:28966959 PMCid:PMC5559941.
Yu J, Liang X, Chen Y, Huang F, Fan W, Xue J, et al. Hepatocellular carcinoma with worsened hypoglycemia after transarterial chemoembolization: a case report and systematic review. Int J Clin Exp Pathol. 2020;13(12):3167-73.
Chowdhury TA, Jacob P. Challenges in the management of people with diabetes and cancer. Diabet Med. 2019;36(7):795-802. PMid:30706527.
Milluzzo A, Vigneri P, Martorana F, Vigneri R, Sciacca L. Type 2 diabetes and cancer: problems and suggestions for best patient management. Explor Med. 2020;1:184-204.
Gallo M, Muscogiuri G, Felicetti F, al e. Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. Metab Clin Exp. 2018;78:141-54. PMid:28993227.
Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012;7(3):e33411. PMid:22448244 PMCid:PMC3308971.
Villani LA, Smith BK, Marcinko K, et al. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab. 2016;5(10):1048-56. PMid:27689018 PMCid:PMC5034684.
Hung MH, Chen YL, Chen LJ, et al. Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation. Cell Death Dis. 2019;10(6):420. PMid:31142735 PMCid:PMC6541593.